BzATP (triethylammonium)

BzATP triethylammonium acts as a P2X receptor agonist with pEC50s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively[1]. BzATP triethylammonium is potent at P2X7 receptors with EC50s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively[2].

Product Specifications

CAS Number

[112898-15-4]

Product Name Alternative

Benzoylbenzoyl-ATP (triethylammonium)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

P2X Receptor

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/3-bzatp-triethylammonium.html

Purity

95.0

Solubility

10 mM in DMSO

Smiles

NC1=C2C(N([C@@H]3O[C@H](COP(OP(OP(O)(O)=O)(O)=O)(O)=O)[C@@H](OC(C4=CC=C(C=C4)C(C5=CC=CC=C5)=O)=O)[C@H]3O)C=N2)=NC=N1.CCN(CC)CC

Molecular Formula

C30H39N6O15P3

Molecular Weight

816.58

Precautions

P261-P280-P302+P352

References & Citations

[1]B R Bianchi, et al. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol. 1999 Jul 2;376 (1-2) :127-38.|[2]Mark T Young, et al. Amino acid residues in the P2X7 receptor that mediate differential sensitivity to ATP and BzATP. Mol Pharmacol. 2007 Jan;71 (1) :92-100.|[3]Zhenhua Ji, et al. Involvement of P2X 7 Receptor in Proliferation and Migration of Human Glioma Cells. Biomed Res Int. 2018 Jan 9;2018:8591397.|[4]Xiuwen Wu, et al. Systemic blockade of P2X7 receptor protects against sepsis-induced intestinal barrier disruption. Sci Rep. 2017 Jun 29;7 (1) :4364.